Answers are grounded in this paper and cite their sources.
Prostate cancer is a leading cause of cancer death in men, with advanced disease exhibiting poor treatment response and low long-term survival. Abiraterone acetate (AbiA) is a progesterone derivative used to treat metastatic prostate cancer, exhibits poor aqueous solubility and low bioavailability, which may result in subtherapeutic drug exposure at the tumor site, and reduced therapeutic efficacy. The present study aims to develop AbiA-loaded nanostructured lipid carriers using the “Quality by Design” strategy in JMP ® Pro. A Plackett-Burman Design was employed for screening significant variables, followed by a Central Composite Design for formulation optimization. The optimized AbiA-NLCs had a particle size of 143.43 ± 2.10 nm, a polydispersity index of 0.164 ± 0.01, a zeta potential of -10.83 ± 0.20 mV, and an entrapment efficiency of 88.76 ± 1.10%. The SEM analysis demonstrated that particles are uniform and spherical. In vitro drug release of AbiA-NLCs in pH 7.4 phosphate-buffered saline with 1% β-cyclodextrin showed improved and sustained drug release compared to AbiA. The optimized AbiA-NLCs showed a nearly two-fold increase in anticancer activity against PC-3 cells, compared to AbiA. Cellular uptake, apoptosis, cell cycle, and colony-forming assays consistently demonstrated the improved anticancer potential of the developed AbiA-NLCs.
No takes yet. Share an insight, caveat, or question.
Peddinti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: